SCHEMBL5114553

SCHEMBL5114553

CCOC(=O)CCCCSc1nc2cc(C#N)ccc2n1C(C(=O)O)C(C)(C)C

nearest known ligand 0.47

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
PTGDR2 Q9Y5Y4 4/20 0.47
HPGD P15428 6/20 0.37
KDM4E B2RXH2 3/20 0.37
MAPT P10636 3/20 0.37
GLA P06280 1/20 0.37
GNRHR P30968 1/20 0.37
ALDH1A1 P00352 4/20 0.35
GAA P10253 3/20 0.35
NPC1 O15118 1/20 0.35
RAB9A P51151 1/20 0.35
L3MBTL1 Q9Y468 2/20 0.35
KMT2A Q03164 2/20 0.35
MEN1 O00255 1/20 0.35
BRCA1 P38398 1/20 0.35
NPSR1 Q6W5P4 1/20 0.34
POLB P06746 2/20 0.34
PPOX P50336 2/20 0.34
TSHR P16473 1/20 0.34
LMNA P02545 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5106754 0.87 PTGDR2 (0.49) PTGDR2HPGDKDM4EMAPTGLA
SCHEMBL5107639 0.85 PTGDR2 (0.48) PTGDR2HPGDKDM4EMAPTGLA
SCHEMBL5114192 0.85 PTGDR2 (0.65) PTGDR2KDM4EMAPTGAAL3MBTL1
SCHEMBL5112911 0.84 PTGDR2 (0.66) PTGDR2KDM4EMAPTGAAL3MBTL1
SCHEMBL5122736 0.84 PTGDR2 (0.47) PTGDR2KDM4EMAPTGNRHRALDH1A1
SCHEMBL5114872 0.82 PTGDR2 (0.64) PTGDR2KDM4EMAPTGAAL3MBTL1
SCHEMBL5106157 0.81 PTGDR2 (0.71) PTGDR2KMT2AMEN1POLB
SCHEMBL5112183 0.81 PTGDR2 (0.46) PTGDR2KMT2AMEN1POLB
SCHEMBL5121751 0.79 PTGDR2 (0.49) PTGDR2HPGDKDM4EMAPTGLA
SCHEMBL5115383 0.73 PTGDR2 (0.51) PTGDR2MAPTGNRHRNPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8273740-B2 antiallergen; not direct way to change nature of immunological response to allergen; G-protein-coupled \"chemoattractant receptor-homologous molecule expressed on Th2 cells (CRTH2)\" antagonist for prostaglandin PGD2, that mediates PGD2-dependent migration of blood Th2 cells; ; asthma, rhinitis, COPD ACTELION PHARMACEUTICALS, LTD. (CH) 2012-09-25 US disclosed
US-20080108638-A1 2-Sulfanyl-Benzoimidazol-1-Yl-Acetic Acid Derivatives as Crth2 Antagonists ACTELION PHARMACEUTICALS,LTD. (CH) 2008-05-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080108638-A1 2-Sulfanyl-Benzoimidazol-1-Yl-Acetic Acid Derivatives as Crth2 Antagonists HRH2, HRH1, HRH3 PTGDR2 12/4885HPGD 169/4885KDM4E 4631/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.